A hospice vendor comparison is objective when every option answers the same set of questions, using the same evidence standard, rather than each vendor being evaluated on the strengths it chooses to highlight in its own pitch. Most comparisons drift away from objectivity not because anyone is being dishonest, but because it's easier to compare Vendor A's best feature against Vendor B's weakest one, simply because that's what each sales conversation emphasized.
For a COO responsible for operations across multiple hospice locations, an unstructured comparison is a real risk. The wrong choice affects nurse workflows, delivery reliability, and predictable per-patient-day (PPD) pharmacy spend for years, not just the first quarter after signing.
A sales demo is designed, reasonably, to show a product at its best. That is not dishonest, it is simply the nature of a sales conversation, and it means a COO who bases a comparison purely on impressions from separate demos is effectively comparing each vendor's best day against every other vendor's best day, with no consistent measuring stick between them. The fix is not to distrust every demo. It is to structure the comparison so demos answer pre-set questions instead of setting the questions themselves.
The most reliable way to keep a comparison objective is to build the evaluation matrix before the first sales call, not during it. Set the categories and the evidence standard for each one up front.
Once every vendor has answered the same questions, score each category on a simple scale and weight the categories that matter most to your organization. A hospice prioritizing rapid multi-location growth may weight standardization and scalability heavily. A hospice focused on turning around a nurse burnout problem may weight support responsiveness and workflow simplicity instead.
Weighting is the step most comparisons skip, and it is the one that actually makes the process objective. Without it, every category counts equally by default, which quietly favors whichever vendor happens to be strong across the board rather than the vendor best suited to the specific problem your organization is trying to solve this year.
BetterRX is built to be evaluated this way. On the operational efficiency and timeliness categories central to a COO-led comparison, BetterRX’s Voice of the Customer survey across six consecutive years found 92.6% satisfaction for “Timeliness to get medications when needed” and 91.2% satisfaction for “More nurse-patient time by reducing delays.” Because any satisfaction statistic should come with its survey population, here is BetterRX’s: 94.3% overall client satisfaction across 30+ evaluation areas, based on feedback from 169 hospice organizations (BetterRX’s 2026 Voice of the Customer survey).
On the support category, the average time to access 24/7 pharmacist and tech support is 7 seconds (2026 Voice of Customer Survey Results | Hospice Medication Management Insights | BetterRX). On pricing structure, BetterRX provides transparent, pass-through pricing and doesn’t mark up medication or delivery costs.
On the multi-location standardization category, Intelligent Medication Management embeds organizational best practices directly into the ordering and approval workflow, so the platform helps every clinician make more consistent decisions, regardless of location, with less reliance on individual memory or repetitive training.
(Source: www.betterrx.com/voice-customer-results-26)
That response speaks directly to the support category on the comparison matrix above, and it's the kind of specific, sourced evidence a COO should be requesting from every vendor on the shortlist, not just the one currently being read about.
Even a well-built comparison matrix can quietly lose its objectivity if a few common mistakes creep into the process. Watching for these keeps the comparison honest from the first call to the final decision.
A well-run comparison ends with a documented decision, not just a gut call. That documentation protects organizational growth by giving future leadership a clear record of why the partner was chosen, and it protects financial stewardship by making the pricing structure and expected outcomes explicit from day one.
To see how the matrix plays out, picture a COO overseeing eight hospice locations across three states, evaluating two finalists after a first round of demos. The COO weights multi-location standardization and support responsiveness most heavily, since those are the two areas causing the most friction today, and weights pricing structure and platform design as secondary factors since both finalists priced within a similar range.
Finalist A scores well on platform design but could only describe standardization in general terms, without a specific mechanism for keeping formulary and ordering rules consistent across locations with different EMRs. Finalist B provided a documented example of how its platform embeds the same clinical and financial standards at every location regardless of EMR, along with an actual average support response time backed by a named, sourced survey.
Weighted for this COO's specific priorities, Finalist B comes out ahead, not because it is a "better company" in the abstract, but because its documented strengths line up with the operational problems this specific organization is trying to solve. A different COO, weighting the same two finalists against different priorities, could reasonably reach a different conclusion, which is exactly why the weighting step matters as much as the scoring step.